This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Marketing

Sep. 10, 2009

Popping Pills

Congress has provided two special incentives for pharmaceutical companies to innovate: patent term extension and FDA marketing exclusivity, writes Antonia Sequeira.

By Antonia Sequeira

Pharmaceutical companies spend years of time and hundreds of millions of dollars to develop each new therapeutic drug, and their return on investment hinges on exclusive sales of those new drugs. Yet, the 20-year patent term clock starts ticking as soon as patents are filed on new candidate compounds, long before a drug is clinically tested and approved for sale by the Food and Drug Administration. Recognizing this, Congress provided t...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up